000285250 001__ 285250
000285250 005__ 20240229155105.0
000285250 0247_ $$2doi$$a10.1016/j.ccell.2023.08.008
000285250 0247_ $$2pmid$$apmid:37683639
000285250 0247_ $$2ISSN$$a1535-6108
000285250 0247_ $$2ISSN$$a1878-3686
000285250 0247_ $$2altmetric$$aaltmetric:153903802
000285250 037__ $$aDKFZ-2023-02285
000285250 041__ $$aEnglish
000285250 082__ $$a610
000285250 1001_ $$0P:(DE-He78)b5b786a7a28d851956ba90aa9451887a$$aMiao, Beiping$$b0$$eFirst author$$udkfz
000285250 245__ $$aCMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1.
000285250 260__ $$aNew York, NY$$bElsevier$$c2023
000285250 3367_ $$2DRIVER$$aarticle
000285250 3367_ $$2DataCite$$aOutput Types/Journal article
000285250 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1699353326_10419
000285250 3367_ $$2BibTeX$$aARTICLE
000285250 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000285250 3367_ $$00$$2EndNote$$aJournal Article
000285250 500__ $$aDKFZ-ZMBH Alliance / #EA:D250#LA:D250#
000285250 520__ $$aThe dysregulated expression of immune checkpoint molecules enables cancer cells to evade immune destruction. While blockade of inhibitory immune checkpoints like PD-L1 forms the basis of current cancer immunotherapies, a deficiency in costimulatory signals can render these therapies futile. CD58, a costimulatory ligand, plays a crucial role in antitumor immune responses, but the mechanisms controlling its expression remain unclear. Using two systematic approaches, we reveal that CMTM6 positively regulates CD58 expression. Notably, CMTM6 interacts with both CD58 and PD-L1, maintaining the expression of these two immune checkpoint ligands with opposing functions. Functionally, the presence of CMTM6 and CD58 on tumor cells significantly affects T cell-tumor interactions and response to PD-L1-PD-1 blockade. Collectively, these findings provide fundamental insights into CD58 regulation, uncover a shared regulator of stimulatory and inhibitory immune checkpoints, and highlight the importance of tumor-intrinsic CMTM6 and CD58 expression in antitumor immune responses.
000285250 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000285250 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000285250 7001_ $$0P:(DE-He78)9465b7d096574a9f1f1691e2fd17db93$$aHu, Zhaoqing$$b1$$eFirst author$$udkfz
000285250 7001_ $$aMezzadra, Riccardo$$b2
000285250 7001_ $$aHoeijmakers, Lotte$$b3
000285250 7001_ $$aFauster, Astrid$$b4
000285250 7001_ $$0P:(DE-He78)842f32f9066384840481c90552ab2cff$$aDu, Shangce$$b5$$udkfz
000285250 7001_ $$aYang, Zhi$$b6
000285250 7001_ $$0P:(DE-He78)2119821cf3458781f06157c7aeecba8b$$aSator-Schmitt, Melanie$$b7$$udkfz
000285250 7001_ $$0P:(DE-He78)1a89b3d8ddc335a4c010ef9d5efabc7a$$aEngel, Helena$$b8$$udkfz
000285250 7001_ $$aLi, Xueshen$$b9
000285250 7001_ $$aBroderick, Caroline$$b10
000285250 7001_ $$aJin, Guangzhi$$b11
000285250 7001_ $$aGomez-Eerland, Raquel$$b12
000285250 7001_ $$aRozeman, Lisette$$b13
000285250 7001_ $$aLei, Xin$$b14
000285250 7001_ $$0P:(DE-He78)3be9a4b1ad5dc609e4b60c04de3f9f4d$$aMatsuo, Hitoshi$$b15$$udkfz
000285250 7001_ $$0P:(DE-He78)8b693edfb7c78bb156cc92812eec1c55$$aYang, Chen$$b16$$udkfz
000285250 7001_ $$aHofland, Ingrid$$b17
000285250 7001_ $$aPeters, Dennis$$b18
000285250 7001_ $$aBroeks, Annegien$$b19
000285250 7001_ $$0P:(DE-He78)26b012bbbc85e8736a8979469a69d9f6$$aLaport, Elke$$b20$$udkfz
000285250 7001_ $$0P:(DE-He78)0d8fa784ae0ac78e2f5ef9159c0dc608$$aFitz, Annika$$b21$$udkfz
000285250 7001_ $$0P:(DE-He78)bf4fb8cc5fd36d4f939e03d15dd34019$$aZhao, Xiyue$$b22$$udkfz
000285250 7001_ $$0P:(DE-He78)c64a2551addbc772856c898989c2da62$$aMahmoud, Mohamed Abdalla Abdelaziz$$b23$$udkfz
000285250 7001_ $$0P:(DE-He78)88de8ba75b18dd92d742eb7eab04a1b3$$aMa, Xiujian$$b24$$udkfz
000285250 7001_ $$0P:(DE-He78)3c4e3363a68498c72ad042b849e11f3a$$aSander, Sandrine$$b25$$udkfz
000285250 7001_ $$0P:(DE-He78)76aeb2431f7458c9261e69c5420390c6$$aLiu, Hai-Kun$$b26$$udkfz
000285250 7001_ $$0P:(DE-He78)0b7ce76033a6756b91f5bfb12602e20b$$aCui, Guoliang$$b27$$udkfz
000285250 7001_ $$aGan, Yu$$b28
000285250 7001_ $$aWu, Wei$$b29
000285250 7001_ $$aXiao, Yanling$$b30
000285250 7001_ $$aHeck, Albert J R$$b31
000285250 7001_ $$aGuan, Wenxian$$b32
000285250 7001_ $$aLowe, Scott W$$b33
000285250 7001_ $$aHorlings, Hugo M$$b34
000285250 7001_ $$aWang, Cun$$b35
000285250 7001_ $$aBrummelkamp, Thijn R$$b36
000285250 7001_ $$aBlank, Christian U$$b37
000285250 7001_ $$aSchumacher, Ton N M$$b38
000285250 7001_ $$0P:(DE-He78)ef40d75e5564c492ee57b4262fc016fe$$aSun, Chong$$b39$$eLast author$$udkfz
000285250 773__ $$0PERI:(DE-600)2074034-7$$a10.1016/j.ccell.2023.08.008$$gVol. 41, no. 10, p. 1817 - 1828.e9$$n10$$p1817 - 1828.e9$$tCancer cell$$v41$$x1535-6108$$y2023
000285250 909CO $$ooai:inrepo02.dkfz.de:285250$$pVDB
000285250 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b5b786a7a28d851956ba90aa9451887a$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000285250 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9465b7d096574a9f1f1691e2fd17db93$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000285250 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)842f32f9066384840481c90552ab2cff$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000285250 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2119821cf3458781f06157c7aeecba8b$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000285250 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1a89b3d8ddc335a4c010ef9d5efabc7a$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000285250 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3be9a4b1ad5dc609e4b60c04de3f9f4d$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000285250 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8b693edfb7c78bb156cc92812eec1c55$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000285250 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)26b012bbbc85e8736a8979469a69d9f6$$aDeutsches Krebsforschungszentrum$$b20$$kDKFZ
000285250 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0d8fa784ae0ac78e2f5ef9159c0dc608$$aDeutsches Krebsforschungszentrum$$b21$$kDKFZ
000285250 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bf4fb8cc5fd36d4f939e03d15dd34019$$aDeutsches Krebsforschungszentrum$$b22$$kDKFZ
000285250 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c64a2551addbc772856c898989c2da62$$aDeutsches Krebsforschungszentrum$$b23$$kDKFZ
000285250 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)88de8ba75b18dd92d742eb7eab04a1b3$$aDeutsches Krebsforschungszentrum$$b24$$kDKFZ
000285250 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3c4e3363a68498c72ad042b849e11f3a$$aDeutsches Krebsforschungszentrum$$b25$$kDKFZ
000285250 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)76aeb2431f7458c9261e69c5420390c6$$aDeutsches Krebsforschungszentrum$$b26$$kDKFZ
000285250 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0b7ce76033a6756b91f5bfb12602e20b$$aDeutsches Krebsforschungszentrum$$b27$$kDKFZ
000285250 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ef40d75e5564c492ee57b4262fc016fe$$aDeutsches Krebsforschungszentrum$$b39$$kDKFZ
000285250 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000285250 9141_ $$y2023
000285250 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER CELL : 2022$$d2023-10-24
000285250 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-24
000285250 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-24
000285250 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-24
000285250 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-24
000285250 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-24
000285250 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-24
000285250 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-24
000285250 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-24
000285250 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-24
000285250 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-24
000285250 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-24
000285250 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-24
000285250 915__ $$0StatID:(DE-HGF)9950$$2StatID$$aIF >= 50$$bCANCER CELL : 2022$$d2023-10-24
000285250 9202_ $$0I:(DE-He78)D250-20160331$$kD250$$lNWG Krebs-Immunregulation$$x0
000285250 9200_ $$0I:(DE-He78)D250-20160331$$kD250$$lNWG Krebs-Immunregulation$$x0
000285250 9201_ $$0I:(DE-He78)D250-20160331$$kD250$$lNWG Krebs-Immunregulation$$x0
000285250 9201_ $$0I:(DE-He78)A240-20160331$$kA240$$lA240 Molekulare Neurogenetik$$x1
000285250 9201_ $$0I:(DE-He78)D180-20160331$$kD180$$lNWG Erworbene Immunität und Lymphome$$x2
000285250 9201_ $$0I:(DE-He78)D192-20160331$$kD192$$lT-Zell-Metabolismus$$x3
000285250 980__ $$ajournal
000285250 980__ $$aVDB
000285250 980__ $$aI:(DE-He78)D250-20160331
000285250 980__ $$aI:(DE-He78)A240-20160331
000285250 980__ $$aI:(DE-He78)D180-20160331
000285250 980__ $$aI:(DE-He78)D192-20160331
000285250 980__ $$aUNRESTRICTED